Form 4: Danimer Scientific Director Stephen Croskrey Reports Acquisition of Restricted Stock Units

Director Stephen Croskrey reports acquisition of 1,125 restricted stock units in Danimer Scientific, Inc.

Summary

• Stephen Croskrey, a director of Danimer Scientific, Inc., filed a Form 4 on January 3, 2025, reporting a transaction.
• On January 1, 2025, Croskrey acquired 1,125 restricted stock units (RSUs) representing a contingent right to receive one share of Danimer Scientific Class A common stock each.
• These RSUs were granted as non-employee director compensation under the company's 2020 Long-Term Incentive Plan.
• The RSUs will vest on July 9, 2025, contingent upon Croskrey's continued service as a director.
• The price of the derivative security is $0.
• On November 12, 2024, the common stock of Danimer Scientific, Inc. reverse split 1 for 40.

Sentiment

Score: 7

Explanation: The document reflects a standard transaction related to director compensation, indicating a neutral to slightly positive sentiment due to alignment of interests.

Positives

• The grant of RSUs aligns the director's interests with the long-term performance of the company.
• The vesting schedule encourages continued service and commitment from the director.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting of the RSUs.

Industry Context

This filing is a routine disclosure of director compensation in the form of equity, which is a common practice in publicly traded companies to align management and shareholder interests.

Stakeholder Impact

• The RSU grant aligns the director's interests with those of shareholders, potentially encouraging decisions that benefit the company's long-term value.

Key Dates

Keywords

Danimer Scientific, Director Compensation, Restricted Stock Units, RSU, Form 4, Beneficial Ownership, Stephen Croskrey, DNMR